Sunitinib for Advanced Thymus Cancer Following Earlier Treatment

NCT01621568 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

56

Enrollment

NIH

Sponsor class

Conditions

Thymoma
Thymus Neoplasms

Interventions

DRUG: Sunitinib
DRUG: Sunitinib

Sponsor

National Cancer Institute (NCI)

Collaborators

[object Object]